ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP
BAUDETTE, Minn., Jan. 23, 2024 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq:ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg.
Related news for (ANIP)
- ANI Pharmaceuticals Announces Presentation of New Preclinical Data
- ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
- ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance
- ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model
- ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets